INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149901, 'Tocilizumab', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150064/', '', 'Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149902, 'Tofacitinib', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150065/', '', 'Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Baricitinib, Tofacitinib, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149903, 'Tolazoline', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150066/', '', 'Rabeprazole, Phenylbutazone, Indomethacin, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, Meclofenamic acid, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149904, 'Topotecan', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150067/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149905, 'Toremifene', 'Ozanimod', 'Major', 'Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150068/', '', 'Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149906, 'Torasemide', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150069/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149907, 'Tositumomab', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150070/', '', 'Iodide I-131', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149908, 'Trabectedin', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150071/', '', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149909, 'Trandolapril', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150072/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149910, 'Tranylcypromine', 'Ozanimod', 'Major', 'Coadministration of ozanimod with monoamine oxidase inhibitors (MAOIs) may increase the risk of hypertensive crisis. The proposed mechanism may involve inhibition of monoamine oxidase by the metabolites of ozanimod. In addition, MAO-B inhibitors may decrease exposure of the active metabolites of ozanimod which may lead to loss of ozanimod efficacy. This interaction has not been studied in a clinical setting.', 'DDInter', 'Coadministration of ozanimod with MAOIs is considered contraindicated. At least 14 days should elapse between discontinuation of ozanimod and initiation of treatment with MAOIs.', 'Synergism', 'Coadministration of ozanimod with MAOIs is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150073/', '', 'Viloxazine, Esketamine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149911, 'Treprostinil', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150074/', '', 'Betrixaban, Apixaban, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149912, 'Triamcinolone (ophthalmic)', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150075/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Dexamethasone, Ciclesonide, More', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Anifrolumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149913, 'Triamterene', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150076/', '', 'Finerenone', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149914, 'Trichlormethiazide', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150077/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149915, 'Trichophyton mentagrophytes', 'Ozanimod', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150078/', '', 'Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149916, 'Triclabendazole', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150079/', '', 'Praziquantel, Oxamniquine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149917, 'Trifluoperazine', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150080/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149918, 'Triflupromazine', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150081/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149919, 'Alimemazine', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150082/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Fexofenadine, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149920, 'Trimethaphan', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150083/', '', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149921, 'Trimetrexate', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150084/', '', 'Tinidazole, Quinacrine, Secnidazole, Atovaquone, Nitazoxanide', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149922, 'Trimipramine', 'Ozanimod', 'Moderate', 'Coadministration of adrenergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may precipitate severe hypertensive reactions and hyperpyrexia. Coadministration of serotonergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150085/', '', 'Viloxazine, Esketamine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149923, 'Tryptophan', 'Ozanimod', 'Moderate', 'Coadministration of serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), 5-HT1 receptor agonists (triptans), ergot alkaloids, buspirone, dextromethorphan, St. John''s wort) with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150086/', '', 'Viloxazine, Esketamine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149924, 'Tuberculin purified protein derivative', 'Ozanimod', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150087/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149925, 'Typhoid vaccine (inactivated)', 'Ozanimod', 'Moderate', 'INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during ozanimod therapy is generally safe but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to three months after discontinuation of ozanimod therapy.', 'DDInter', 'Immune response to vaccines may be reduced during and for up to three months after discontinuation of ozanimod therapy. In patients who have recently been vaccinated, ozanimod therapy should preferably be postponed for one month to allow the full effect of vaccination to occur.', 'Others', 'Immune response to vaccines may be reduced during and for up to three months after discontinuation of ozanimod therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150088/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149926, 'Typhoid vaccine (live)', 'Ozanimod', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during ozanimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.', 'DDInter', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment. If live attenuated vaccine immunizations are required, administration should occur at least 1 month prior to initiation of ozanimod. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ozanimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ozanimod. In patients who have recently been vaccinated, ozanimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.', 'Others', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150089/', '', 'Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, Voclosporin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149927, 'Upadacitinib', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150090/', '', 'Upadacitinib, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149928, 'Uracil mustard', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150091/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149929, 'Ustekinumab', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150092/', '', 'Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ustekinumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149930, 'Vandetanib', 'Ozanimod', 'Major', 'Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.', 'Synergism', 'Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150093/', '', 'Axitinib, Larotrectinib, Fedratinib, Tucatinib, Imatinib, Trametinib, Erlotinib, Dabrafenib, Selumetinib, Erdafitinib, Nintedanib, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149931, 'Varicella Zoster Vaccine (Recombinant)', 'Ozanimod', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during ozanimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.', 'DDInter', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment. If live attenuated vaccine immunizations are required, administration should occur at least 1 month prior to initiation of ozanimod. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ozanimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ozanimod. In patients who have recently been vaccinated, ozanimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.', 'Others', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150094/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149932, 'Vasopressin', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150095/', '', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149933, 'Vemurafenib', 'Ozanimod', 'Major', 'Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.', 'Synergism', 'Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150096/', '', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149934, 'Venetoclax', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150097/', '', 'Pertuzumab, Vismodegib, Sotorasib, Belzutifan, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, Vorinostat, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149935, 'Venlafaxine', 'Ozanimod', 'Moderate', 'Coadministration of adrenergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may precipitate severe hypertensive reactions and hyperpyrexia. Coadministration of serotonergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150098/', '', 'Viloxazine, Esketamine', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149936, 'Vilazodone', 'Ozanimod', 'Moderate', 'Coadministration of serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), 5-HT1 receptor agonists (triptans), ergot alkaloids, buspirone, dextromethorphan, St. John''s wort) with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150099/', '', 'Viloxazine, Esketamine', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149937, 'Vinblastine', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150100/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149938, 'Vincristine (liposome)', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150101/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149939, 'Vinorelbine', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150102/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149940, 'Voriconazole', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', 'DDInter', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150103/', '', 'Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Flucytosine, Anidulafungin', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149941, 'Vortioxetine', 'Ozanimod', 'Moderate', 'Coadministration of adrenergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may precipitate severe hypertensive reactions and hyperpyrexia. Coadministration of serotonergic agents with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with agents that possess adrenergic and serotonergic effects should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150104/', '', 'Viloxazine, Esketamine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149942, 'Xylometazoline (nasal)', 'Ozanimod', 'Moderate', 'By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors).', 'DDInter', 'Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).', 'Synergism', 'Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150105/', '', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149943, 'Yellow Fever Vaccine', 'Ozanimod', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during ozanimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence.', 'DDInter', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment. If live attenuated vaccine immunizations are required, administration should occur at least 1 month prior to initiation of ozanimod. Patients without a healthcare professional confirmed history of varicella or without documentation of a full course of vaccination against varicella-zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment with ozanimod. For antibody-negative patients, a full course of vaccination with varicella vaccine is recommended prior to treatment with ozanimod. In patients who have recently been vaccinated, ozanimod therapy should be postponed for 4 weeks to allow the full effect of vaccination to occur.', 'Others', 'The use of live attenuated vaccines should be avoided during and for up to 3 months after discontinuing ozanimod treatment.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150106/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149944, 'Zanubrutinib', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150107/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Axitinib, Larotrectinib, Fedratinib, Tucatinib, Imatinib, Trametinib, Erlotinib, Dabrafenib, Selumetinib, Erdafitinib, Nintedanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149945, 'Ziprasidone', 'Ozanimod', 'Major', 'Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', 'DDInter', 'Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150108/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149946, 'Aflibercept', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150109/', '', 'Bevacizumab, Verteporfin, Pertuzumab, Vismodegib, Sotorasib, Belzutifan, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149947, 'Zolmitriptan', 'Ozanimod', 'Moderate', 'Coadministration of serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), 5-HT1 receptor agonists (triptans), ergot alkaloids, buspirone, dextromethorphan, St. John''s wort) with drugs that possess monoamine oxidase inhibition (MAOI) activity may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.', 'DDInter', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible. Blood pressure and other vitals should be monitored if coadministration is required.', 'Synergism', 'Until more information is available, concomitant use of ozanimod with serotonergic agents should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150110/', '', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149948, 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Palbociclib', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', 'DDInter', 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.', 'Others', 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150111/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149949, 'Aminoglutethimide', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150112/', '', 'Tamoxifen, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Fedratinib, Vandetanib, Afatinib, Tivozanib, Lorlatinib, Regorafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149950, 'Amprenavir', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150113/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149951, 'Palbociclib', 'Astemizole', 'Moderate', 'Coadministration with palbociclib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever palbociclib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150114/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149952, 'Bacillus calmette-guerin substrain tice live antigen', 'Palbociclib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150115/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149953, 'Berotralstat', 'Palbociclib', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Absorption', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150116/', '', 'Copanlisib, Lenvatinib, Erdafitinib, Dabrafenib, Abemaciclib, Vandetanib, Trametinib, Dacomitinib, Alectinib, Binimetinib', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149954, 'Bifidobacterium longum infantis', 'Palbociclib', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150117/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149955, 'Boceprevir', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150118/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149956, 'Butabarbital', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150119/', '', 'Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More', 'Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Vandetanib, Afatinib, Tivozanib, Lorlatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149957, 'Candida albicans', 'Palbociclib', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150120/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149958, 'Cerivastatin', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150121/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149959, 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Palbociclib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150122/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149960, 'Cisapride', 'Palbociclib', 'Moderate', 'Coadministration with palbociclib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever palbociclib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150123/', '', 'Metoclopramide', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149961, 'Clotrimazole', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150124/', '', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, More', 'Dabrafenib, Dacomitinib, Vemurafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, Alpelisib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149962, 'Coccidioides immitis spherule', 'Palbociclib', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150125/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149963, 'Copanlisib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'Caution is advised when copanlisib is used with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as nausea, vomiting, diarrhea, stomatitis, hyperglycemia, hypertension, noninfectious pneumonitis, cutaneous reactions (e.g., exfoliative dermatitis, maculopapular rash), anemia, neutropenia, thrombocytopenia, and infections. Dosage adjustments for copanlisib may be necessary and should be done in accordance with the product labeling.', 'Metabolism', 'Caution is advised when copanlisib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150126/', '', 'Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149964, 'Echinacea', 'Palbociclib', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150127/', '', 'Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149965, 'Efalizumab', 'Palbociclib', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150128/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149966, 'Entrectinib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.', 'DDInter', 'Caution is advised when entrectinib is used with CYP450 3A4 inhibitors. Pharmacologic response to entrectinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the entrectinib dosage adjusted as necessary in accordance with the product labeling. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised when entrectinib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150129/', '', 'Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149967, 'Enzalutamide', 'Palbociclib', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150130/', '', 'Tamoxifen, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone, Exemestane', 'Alectinib, Dacomitinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149968, 'Ergometrine', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', 'DDInter', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150131/', '', 'Misoprostol, Dinoprostone, Oxytocin', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149969, 'Ergotamine', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', 'DDInter', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150132/', '', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149970, 'Escitalopram', 'Palbociclib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150133/', '', 'Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More', 'Dacomitinib, Pexidartinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149971, 'Eslicarbazepine', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150134/', '', 'Dabrafenib, Asciminib, Dacomitinib, Fedratinib, Vandetanib, Ibrutinib, Afatinib, Tivozanib, Regorafenib, Ruxolitinib, Lenvatinib, More', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149972, 'Etanercept', 'Palbociclib', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150135/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149973, 'Etravirine', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150136/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Futibatinib, Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149974, 'Everolimus', 'Palbociclib', 'Moderate', 'Coadministration with palbociclib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever palbociclib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150137/', '', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Brigatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149975, 'Fedratinib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150138/', '', 'Futibatinib, Fedratinib, Copanlisib, Alpelisib, Vemurafenib, Erlotinib, Lenvatinib, Erdafitinib, Vandetanib, Trametinib, Afatinib, More', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149976, 'Felbamate', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150139/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More', 'Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Dabrafenib, Asciminib, Vandetanib, Neratinib, Afatinib, Trametinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149977, 'Filgrastim', 'Palbociclib', 'Moderate', 'INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.', 'DDInter', 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150140/', '', 'Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Aldesleukin, Pegademase, More', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149978, 'Fingolimod', 'Palbociclib', 'Major', 'Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.', 'DDInter', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.', 'Synergism', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150141/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Selumetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149979, 'Flibanserin', 'Palbociclib', 'Moderate', 'Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.', 'DDInter', 'Caution is advised when flibanserin is used with multiple weak CYP450 3A4 inhibitors. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.', 'Metabolism', 'Caution is advised when flibanserin is used with multiple weak CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150142/', '', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen', 'Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Encorafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149980, 'Fluconazole', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150143/', '', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More', 'Futibatinib, Tucatinib, Regorafenib, Alpelisib, Trametinib, Erdafitinib, Dabrafenib, Nintedanib, Afatinib, Dacomitinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149981, 'Fluvoxamine', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150144/', '', 'Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More', 'Dabrafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Alpelisib, Lenvatinib, Erdafitinib, Alectinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149982, 'Fosamprenavir', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150145/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Futibatinib, Imatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib, Binimetinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149983, 'Fosaprepitant', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150146/', '', 'Sunitinib, Futibatinib, Regorafenib, Copanlisib, Alpelisib, Lenvatinib, Erlotinib, Erdafitinib, Abemaciclib, Vandetanib, Trametinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149984, 'Fosphenytoin', 'Palbociclib', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150147/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More', 'Futibatinib, Lenvatinib, Trametinib, Dacomitinib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149985, 'Fostamatinib', 'Palbociclib', 'Moderate', 'Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.', 'DDInter', 'Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150148/', '', 'Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, More', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149986, 'Ganciclovir', 'Palbociclib', 'Moderate', 'The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.', 'DDInter', 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.', 'Synergism', 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150149/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149987, 'Gilteritinib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.', 'DDInter', 'Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections and stomatitis, and the gilteritinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150150/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, Regorafenib, Ruxolitinib, Erlotinib, More', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149988, 'Glasdegib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when glasdegib is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema and mucositis, and the glasdegib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when glasdegib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150151/', '', 'Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149989, 'Goldenseal', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150152/', '', 'Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Vemurafenib, Lapatinib, Ribociclib, Vandetanib, Capmatinib, Afatinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149990, 'Golimumab', 'Palbociclib', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150153/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149991, 'Grepafloxacin', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150154/', '', 'Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More', 'Dabrafenib, Dacomitinib, Pexidartinib, Capmatinib, Afatinib, Tivozanib, Regorafenib, Alpelisib, Erdafitinib, Ponatinib, Neratinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149992, 'Griseofulvin', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150155/', '', 'Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin', 'Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Vandetanib, Afatinib, Tivozanib, Lorlatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149993, 'Guanfacine', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when guanfacine is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as hypotension, bradycardia and sedation , and the guanfacine dosage adjusted as necessary.', 'Metabolism', 'Caution is advised when guanfacine is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150156/', '', 'Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149994, 'Hepatitis A Vaccine', 'Palbociclib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150157/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149995, 'Hepatitis B Vaccine (Recombinant)', 'Palbociclib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150158/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149996, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Palbociclib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150159/', '', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149997, 'Idelalisib', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150160/', '', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 'Idelalisib, Tivozanib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149998, 'Imatinib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.', 'Metabolism', 'Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150161/', '', 'Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More', 'Sunitinib, Regorafenib, Imatinib, Lenvatinib, Erlotinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (149999, 'Indacaterol', 'Palbociclib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150162/', '', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More', 'Dabrafenib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Lorlatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (150000, 'Indinavir', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', 'DDInter', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/150163/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 'Futibatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 1767369485);
